<p>Biogen（纳斯达克股票代码：BIIB - 获取免费报告）在周四发布的一份研究报告中，Oppenheimer 的股票研究人员将其目标价格从 275.00 美元上调至 300.00 美元，MarketScreener 报道。该券商目前对这家生物技术公司的股票给予 “跑赢大盘” 的评级。Oppenheimer 的目标价格表明，相较于公司之前的收盘价，潜在上涨幅度为 55.47%。</p>
<ul>
<li>2026 年看起来 “必胜” 的 3 只生物技术股票</li>
</ul>
<p>其他一些分析师也对该股票发表了评论。富国银行在 2 月 8 日的研究报告中将 Biogen 的目标价格从 190.00 美元上调至 200.00 美元，并给予公司 “等权重” 评级。摩根士丹利在 4 月 30 日的报告中将 Biogen 的目标价格从 200.00 美元上调至 206.00 美元，并给予公司 “等权重” 评级。花旗在 5 月 1 日的报告中将 Biogen 的目标价格从 190.00 美元上调至 200.00 美元，并给予该股票 “中性” 评级。汇丰银行在 3 月 17 日的研究报告中将 Biogen 的目标价格从 143.00 美元上调至 150.00 美元，并给予公司 “减持” 评级。最后，巴克莱在 2 月 19 日的报告中开始覆盖 Biogen，设定 “等权重” 评级和 185.00 美元的目标价格。一位研究分析师对该股票给予 “强烈买入” 评级，十四位给予 “买入” 评级，十三位给予 “持有” 评级，一位给予 “卖出” 评级。根据 MarketBeat.com 的数据，该股票的共识评级为 “适度买入”，平均目标价格为 215.62 美元。</p>
<p><strong>阅读我们关于 BIIB 的最新报告</strong></p>
<h2>Biogen 股票上涨 0.8%</h2>
<ul>
<li>Biogen 股票正在转变为价值投资</li>
</ul>
<p>周四交易时段，BIIB 的股票上涨 1.60 美元，达到 192.97 美元。该股票的交易量为 207,294 股，而其平均交易量为 1,298,386 股。Biogen 的 1 年最低价为 121.05 美元，1 年最高价为 205.97 美元。该公司的市值为 284.9 亿美元，市盈率为 20.67，市盈增长比率为 1.80，贝塔值为 0.19。该公司的 50 日简单移动平均为 185.15 美元，200 日简单移动平均为 179.24 美元。公司的债务与股本比率为 0.34，流动比率为 3.06，速动比率为 2.41。</p>
<p>Biogen（纳斯达克股票代码：BIIB - 获取免费报告）最后一次公布季度财报是在 4 月 29 日，生物技术公司报告每股收益（EPS）为 3.57 美元，超出市场共识预期的 2.95 美元，超出幅度为 0.62 美元。该季度的营业收入为 24.8 亿美元，而分析师预期为 22.9 亿美元。Biogen 的股本回报率为 12.83%，净利润率为 13.81%。公司的季度收入同比增长 1.9%。在去年同期，公司每股收益为 3.02 美元。Biogen 已将其 2026 财年的指导目标设定为 14.250-15.250 EPS。卖方分析师预测 Biogen 在当前财年将发布 14.21 EPS。</p>
<h2>机构投资者对 Biogen 的看法</h2>
<ul>
<li>这 3 只股票被严重低估：抓住机会</li>
</ul>
<p>机构投资者和对冲基金最近增加或减少了对公司的持股。Reflection Asset Management 在第四季度购买了 Biogen 的新股份，价值约 25,000 美元。WPG Advisers LLC 在第四季度将其在 Biogen 的持股增加了 417.9%。WPG Advisers LLC 现在拥有 145 股生物技术公司的股票，价值 26,000 美元，此前在上个季度又购买了 117 股。First Horizon Corp 在第四季度购买了 Biogen 的新股份，价值 30,000 美元。Root Financial Partners LLC 在第四季度将其在 Biogen 的持股增加了 198.4%。Root Financial Partners LLC 现在拥有 185 股生物技术公司的股票，价值 33,000 美元，此前在上个季度又购买了 123 股。最后，MV Capital Management Inc.在第四季度购买了 Biogen 的新股份，价值 34,000 美元。对冲基金和其他机构投资者持有公司 87.93% 的股票。</p>
<h2>Biogen 新闻摘要</h2>
<p>以下是本周影响 Biogen 的主要新闻：</p>
<ul>
<li>积极情绪：Biogen 报告了其阿尔茨海默病药物 <strong>diranersen (BIIB080)</strong> 的二期临床试验的顶线数据，显示出显著减少 tau 病理和认知衰退减缓的信号，公司表示将推进该项目进入三期/注册开发。文章标题</li>
<li>积极情绪：投资者也欢迎 Biogen 完成 <strong>53 亿美元的 Apellis Pharmaceuticals 收购</strong>，该收购增加了商业产品 <strong>SYFOVRE</strong> 和 <strong>EMPAVELI</strong>，并可能增强短期增长。文章标题</li>
<li>中性情绪：几位分析师在数据发布后维持了 <strong>持有</strong> 评级，认为数据存在混合：生物标志物和认知信号令人鼓舞，但研究 <strong>未达到主要终点</strong>。文章标题</li>
<li>消极情绪：阿尔茨海默病研究的失败使得 diranersen 能否迅速转化为商业价值存在一些不确定性，而 Apellis 交易增加了整合和融资的考虑。文章标题</li>
</ul>
<h2>Biogen 公司简介</h2>
<p>（获取免费报告）</p>
<p>Biogen Inc 是一家跨国生物技术公司，专注于发现、开发和提供神经和神经退行性疾病的治疗方案。公司总部位于马萨诸塞州剑桥，长期以来专注于神经科学，研究和商业活动涵盖多种治疗领域，包括多发性硬化症、脊髓性肌萎缩症和阿尔茨海默病。Biogen 成立于 1978 年，已发展成为一家全球生物制药公司，在北美、欧洲、日本及其他国际市场拥有业务和商业存在。</p>
<p>该公司的市场产品组合历史上包括几种知名的多发性硬化症疗法，如 Avonex、Tysabri 和 Tecfidera，并且它还在追求针对罕见神经疾病和遗传性神经肌肉疾病的治疗。</p>
<h2>另见</h2>
<ul>
<li>五只我们认为比 Biogen 更好的股票</li>
<li>电网正在衰退——是时候购买其替代品了吗？</li>
<li>3 只值得关注的 AI 数据中心股票，适合资本轮换</li>
<li>麦当劳的价格是多年来最低的——这是否意味着它值得购买？</li>
<li>Karman：国防明星在下跌 40% 后前景增强</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QklJQg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="650" height="330" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QklJQg"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Biogen 吗？</h2>
<p>在考虑 Biogen 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Biogen 并不在名单上。</p>
<p>虽然 Biogen 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

BIIB

标普全球医疗股指数 ETF - iShares

动态生物技术与基因组 ETF - Invesco

<p>Oppenheimer 将 Biogen (NASDAQ:BIIB) 的目标股价从 275 美元上调至 300 美元，维持 “跑赢大盘” 的评级。这表明与前一交易日收盘价相比，潜在上涨幅度为 55.47%。其他分析师也调整了他们的目标，普遍评级为 “适度买入”，平均目标为 215.62 美元。Biogen 的股票最近交易价格为 192.97 美元，市值为 284.9 亿美元，市盈率为 20.67</p>

<p>Biogen (NASDAQ:BIIB - Get Free Report) had its target price lifted by equities researchers at Oppenheimer from $275.00 to $300.00 in a research report issued on Thursday,MarketScreener reports. The brokerage presently has an &#34;outperform&#34; rating on the biotechnology company's stock. Oppenheimer's price target indicates a potential upside of 55.47% from the company's previous close.</p>
<div class="lb-trans"><p>Biogen（纳斯达克股票代码：BIIB - 获取免费报告）在周四发布的一份研究报告中，Oppenheimer 的股票研究人员将其目标价格从 275.00 美元上调至 300.00 美元，MarketScreener 报道。该券商目前对这家生物技术公司的股票给予 “跑赢大盘” 的评级。Oppenheimer 的目标价格表明，相较于公司之前的收盘价，潜在上涨幅度为 55.47%。</p>
</div><ul>
<li>3 Biotech Stocks That Look Like “Sure-Fire” Winners in 2026</li>
</ul>
<div class="lb-trans"><ul>
<li>2026 年看起来 “必胜” 的 3 只生物技术股票</li>
</ul>
</div><p>A number of other analysts have also commented on the stock. Wells Fargo &amp; Company boosted their price target on shares of Biogen from $190.00 to $200.00 and gave the company an &#34;equal weight&#34; rating in a research note on Sunday, February 8th. Morgan Stanley lifted their price objective on shares of Biogen from $200.00 to $206.00 and gave the company an &#34;equal weight&#34; rating in a report on Thursday, April 30th. Citigroup upped their target price on shares of Biogen from $190.00 to $200.00 and gave the stock a &#34;neutral&#34; rating in a report on Friday, May 1st. HSBC raised their price target on shares of Biogen from $143.00 to $150.00 and gave the company a &#34;reduce&#34; rating in a research report on Tuesday, March 17th. Finally, Barclays initiated coverage on Biogen in a report on Thursday, February 19th. They set an &#34;equal weight&#34; rating and a $185.00 price objective for the company. One research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, thirteen have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of &#34;Moderate Buy&#34; and an average price target of $215.62.</p>
<div class="lb-trans"><p>其他一些分析师也对该股票发表了评论。富国银行在 2 月 8 日的研究报告中将 Biogen 的目标价格从 190.00 美元上调至 200.00 美元，并给予公司 “等权重” 评级。摩根士丹利在 4 月 30 日的报告中将 Biogen 的目标价格从 200.00 美元上调至 206.00 美元，并给予公司 “等权重” 评级。花旗在 5 月 1 日的报告中将 Biogen 的目标价格从 190.00 美元上调至 200.00 美元，并给予该股票 “中性” 评级。汇丰银行在 3 月 17 日的研究报告中将 Biogen 的目标价格从 143.00 美元上调至 150.00 美元，并给予公司 “减持” 评级。最后，巴克莱在 2 月 19 日的报告中开始覆盖 Biogen，设定 “等权重” 评级和 185.00 美元的目标价格。一位研究分析师对该股票给予 “强烈买入” 评级，十四位给予 “买入” 评级，十三位给予 “持有” 评级，一位给予 “卖出” 评级。根据 MarketBeat.com 的数据，该股票的共识评级为 “适度买入”，平均目标价格为 215.62 美元。</p>
</div><p><strong>Read Our Latest Report on BIIB</strong></p>
<div class="lb-trans"><p><strong>阅读我们关于 BIIB 的最新报告</strong></p>
</div><h2>Biogen Stock Up 0.8%</h2>
<div class="lb-trans"><h2>Biogen 股票上涨 0.8%</h2>
</div><ul>
<li>Biogen Stock Is Mutating Into a Value Play</li>
</ul>
<div class="lb-trans"><ul>
<li>Biogen 股票正在转变为价值投资</li>
</ul>
</div><p>Shares of BIIB traded up $1.60 during trading hours on Thursday, hitting $192.97. The stock had a trading volume of 207,294 shares, compared to its average volume of 1,298,386. Biogen has a 1-year low of $121.05 and a 1-year high of $205.97. The firm has a market capitalization of $28.49 billion, a P/E ratio of 20.67, a price-to-earnings-growth ratio of 1.80 and a beta of 0.19. The firm has a 50 day simple moving average of $185.15 and a 200-day simple moving average of $179.24. The company has a debt-to-equity ratio of 0.34, a current ratio of 3.06 and a quick ratio of 2.41.</p>
<div class="lb-trans"><p>周四交易时段，BIIB 的股票上涨 1.60 美元，达到 192.97 美元。该股票的交易量为 207,294 股，而其平均交易量为 1,298,386 股。Biogen 的 1 年最低价为 121.05 美元，1 年最高价为 205.97 美元。该公司的市值为 284.9 亿美元，市盈率为 20.67，市盈增长比率为 1.80，贝塔值为 0.19。该公司的 50 日简单移动平均为 185.15 美元，200 日简单移动平均为 179.24 美元。公司的债务与股本比率为 0.34，流动比率为 3.06，速动比率为 2.41。</p>
</div><p>Biogen (NASDAQ:BIIB - Get Free Report) last announced its quarterly earnings results on Wednesday, April 29th. The biotechnology company reported $3.57 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.95 by $0.62. The business had revenue of $2.48 billion for the quarter, compared to analyst estimates of $2.29 billion. Biogen had a return on equity of 12.83% and a net margin of 13.81%.The company's quarterly revenue was up 1.9% on a year-over-year basis. During the same quarter in the prior year, the company earned $3.02 earnings per share. Biogen has set its FY 2026 guidance at 14.250-15.250 EPS. Sell-side analysts predict that Biogen will post 14.21 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>Biogen（纳斯达克股票代码：BIIB - 获取免费报告）最后一次公布季度财报是在 4 月 29 日，生物技术公司报告每股收益（EPS）为 3.57 美元，超出市场共识预期的 2.95 美元，超出幅度为 0.62 美元。该季度的营业收入为 24.8 亿美元，而分析师预期为 22.9 亿美元。Biogen 的股本回报率为 12.83%，净利润率为 13.81%。公司的季度收入同比增长 1.9%。在去年同期，公司每股收益为 3.02 美元。Biogen 已将其 2026 财年的指导目标设定为 14.250-15.250 EPS。卖方分析师预测 Biogen 在当前财年将发布 14.21 EPS。</p>
</div><h2>Institutional Investors Weigh In On Biogen</h2>
<div class="lb-trans"><h2>机构投资者对 Biogen 的看法</h2>
</div><ul>
<li>These 3 Stocks Are Screaming Oversold: Seize the Opportunity</li>
</ul>
<div class="lb-trans"><ul>
<li>这 3 只股票被严重低估：抓住机会</li>
</ul>
</div><p>Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Reflection Asset Management purchased a new position in shares of Biogen in the 4th quarter worth approximately $25,000. WPG Advisers LLC boosted its position in Biogen by 417.9% in the fourth quarter. WPG Advisers LLC now owns 145 shares of the biotechnology company's stock worth $26,000 after purchasing an additional 117 shares during the last quarter. First Horizon Corp bought a new position in Biogen in the 4th quarter valued at $30,000. Root Financial Partners LLC increased its position in shares of Biogen by 198.4% during the 4th quarter. Root Financial Partners LLC now owns 185 shares of the biotechnology company's stock valued at $33,000 after purchasing an additional 123 shares during the last quarter. Finally, MV Capital Management Inc. purchased a new stake in shares of Biogen during the 4th quarter valued at $34,000. Hedge funds and other institutional investors own 87.93% of the company's stock.</p>
<div class="lb-trans"><p>机构投资者和对冲基金最近增加或减少了对公司的持股。Reflection Asset Management 在第四季度购买了 Biogen 的新股份，价值约 25,000 美元。WPG Advisers LLC 在第四季度将其在 Biogen 的持股增加了 417.9%。WPG Advisers LLC 现在拥有 145 股生物技术公司的股票，价值 26,000 美元，此前在上个季度又购买了 117 股。First Horizon Corp 在第四季度购买了 Biogen 的新股份，价值 30,000 美元。Root Financial Partners LLC 在第四季度将其在 Biogen 的持股增加了 198.4%。Root Financial Partners LLC 现在拥有 185 股生物技术公司的股票，价值 33,000 美元，此前在上个季度又购买了 123 股。最后，MV Capital Management Inc.在第四季度购买了 Biogen 的新股份，价值 34,000 美元。对冲基金和其他机构投资者持有公司 87.93% 的股票。</p>
</div><h2>Biogen News Summary</h2>
<div class="lb-trans"><h2>Biogen 新闻摘要</h2>
</div><p>Here are the key news stories impacting Biogen this week:</p>
<div class="lb-trans"><p>以下是本周影响 Biogen 的主要新闻：</p>
</div><ul>
<li>Positive Sentiment: Biogen reported topline Phase 2 data for its Alzheimer’s drug <strong>diranersen (BIIB080)</strong> showing robust reductions in tau pathology and signals of slower cognitive decline, and the company said it will advance the program into Phase 3/registrational development. Article Title</li>
<li>Positive Sentiment: Investors also welcomed the completion of Biogen’s <strong>$5.3 billion Apellis Pharmaceuticals acquisition</strong>, which adds commercial products <strong>SYFOVRE</strong> and <strong>EMPAVELI</strong> and could strengthen near-term growth. Article Title</li>
<li>Neutral Sentiment: Several analysts maintained <strong>Hold</strong> ratings after the readout, arguing the data were mixed: biomarker and cognitive signals were encouraging, but the study <strong>missed its primary endpoint</strong>. Article Title</li>
<li>Negative Sentiment: The Alzheimer’s study failure leaves some uncertainty around how quickly diranersen can translate into commercial value, and the Apellis deal adds integration and financing considerations. Article Title</li>
</ul>
<div class="lb-trans"><ul>
<li>积极情绪：Biogen 报告了其阿尔茨海默病药物 <strong>diranersen (BIIB080)</strong> 的二期临床试验的顶线数据，显示出显著减少 tau 病理和认知衰退减缓的信号，公司表示将推进该项目进入三期/注册开发。文章标题</li>
<li>积极情绪：投资者也欢迎 Biogen 完成 <strong>53 亿美元的 Apellis Pharmaceuticals 收购</strong>，该收购增加了商业产品 <strong>SYFOVRE</strong> 和 <strong>EMPAVELI</strong>，并可能增强短期增长。文章标题</li>
<li>中性情绪：几位分析师在数据发布后维持了 <strong>持有</strong> 评级，认为数据存在混合：生物标志物和认知信号令人鼓舞，但研究 <strong>未达到主要终点</strong>。文章标题</li>
<li>消极情绪：阿尔茨海默病研究的失败使得 diranersen 能否迅速转化为商业价值存在一些不确定性，而 Apellis 交易增加了整合和融资的考虑。文章标题</li>
</ul>
</div><h2>Biogen Company Profile</h2>
<div class="lb-trans"><h2>Biogen 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer's disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.</p>
<div class="lb-trans"><p>Biogen Inc 是一家跨国生物技术公司，专注于发现、开发和提供神经和神经退行性疾病的治疗方案。公司总部位于马萨诸塞州剑桥，长期以来专注于神经科学，研究和商业活动涵盖多种治疗领域，包括多发性硬化症、脊髓性肌萎缩症和阿尔茨海默病。Biogen 成立于 1978 年，已发展成为一家全球生物制药公司，在北美、欧洲、日本及其他国际市场拥有业务和商业存在。</p>
</div><p>The company's marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.</p>
<div class="lb-trans"><p>该公司的市场产品组合历史上包括几种知名的多发性硬化症疗法，如 Avonex、Tysabri 和 Tecfidera，并且它还在追求针对罕见神经疾病和遗传性神经肌肉疾病的治疗。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另见</h2>
</div><ul>
<li>Five stocks we like better than Biogen</li>
<li>The Power Grid Is Dying—Is It Time to Buy Its Replacement?</li>
<li>3 AI Data Center Stocks Worth Watching for Capital Rotation</li>
<li>McDonald's Is the Cheapest It’s Been in Years—Does That Make It a Buy?</li>
<li>Karman: Defense Darling's Outlook Strengthens After 40% Drop</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们认为比 Biogen 更好的股票</li>
<li>电网正在衰退——是时候购买其替代品了吗？</li>
<li>3 只值得关注的 AI 数据中心股票，适合资本轮换</li>
<li>麦当劳的价格是多年来最低的——这是否意味着它值得购买？</li>
<li>Karman：国防明星在下跌 40% 后前景增强</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QklJQg" alt="" original-src="https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx?Prefix=NASDAQ&amp;Symbol=BIIB"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Biogen Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Biogen 吗？</h2>
</div><p>Before you consider Biogen, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Biogen 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Biogen wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Biogen 并不在名单上。</p>
</div><p>While Biogen currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Biogen 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Biogen (NASDAQ:BIIB) Stock Price Expected to Rise, Oppenheimer Analyst Says

Market Beat

Biogen

医疗业 ETF - Vanguard

生物科技 ETF - VanEck Vectors

标普生物技术 3 倍做多 - Direxion

2 倍做多纳斯达克生物技术 ETF - ProShares

Invesco Nasdaq Biotechnology ETF

纳斯达克生物科技指数 ETF - iShares Nasdaq

基因改革 ETF - ARK

医药突破 ETF - ALPS

医疗业 ETF - SPDR

美国制药 ETF - iShares

纽交所高增长板生物技术指数 ETF - First Trust

标普生物技术 ETF - SPDR

奥本海默控股

富国银行

摩根士丹利

花旗

汇丰

汇丰控股

巴克莱银行

Apellis Pharma

第一地平线

WELLS FARGO & COMPANY DP SHS REP 1/1000TH INT NCUM PFD CL A DD

WELLS FARGO & COMPANY 7.5% PERP CONV PRF CLS 'A' SERIES 'L'

WELLS FARGO & COMPANY DEP SHS REP 1/1000 INT PER PFD SER Y A

WELLS FARGO & COMPANY DP SHS REP 1/1000TH INT NCUM PFD CL A CC

WELLS FARGO & COMPANY 4.75% DEP SHS 1/1000 NCUM PFD CL A SR Z

WELLS FARGO & COMPANY DEP SHS REP 1/1000TH INT PFD SR AA (CLA)

MORGAN STANLEY DEP SHS EA REP 1/1000 SHS NON CUM PFD O

MORGAN STANLEY DEP SHS REPSTG 1/1000TH PFD SER Q

MORGAN STANLEY DEP SHS REPS 1/1000 7.125% PFD E

MORGAN STANLEY NON-CUM DEP SH REP 1/1000 PFD SER I

MORGAN STANLEY 4.875 DEP SHS REP 1/1000 NCUM PFD SR L

MORGAN STANLEY 6.5%DEP SHS REPSTG 1/1000 NON CUM SER P

MORGAN STANLEY DEP SHS REPS 1/1000 PFD SER 'A'

MORGAN STANLEY DEP SHS REPR 1/1000TH INT PFD SER 'F' FX

MORGAN STANLEY DEP SHS REP 1/1000 NON-CUM PFD STK SER K

CITIGROUP INC 6.250 NON CUM SER II PFD WI

HSBC 5xShortSG241213

汇丰控股有限公司

FIRST HORIZON CORPORATION 6.50% DEP SHS REP 1/4000 PER PFD SER E

FIRST HORIZON CORPORATION DEP SHS REP 1/400 NON CUM PER PFD SER C

FIRST HORIZON CORPORATION DEP SHS REP 1/400 NON CUM PER PFD SER B

FIRST HORIZON CORPORATION DEP SH REP 1/4000 INT NON CUM PFD H WI

FIRST HORIZON CORPORATION DEP SHS REPSTG 1/4000TH PERP PFD SER F

Oppenheimer 的分析师表示，Biogen（NASDAQ:BIIB）的股价预计将会上涨